Published in Pharma Investments, Ventures and Law Weekly, August 13th, 2006
An A.G.E. Crosslink Breaker, alagebrium will be tested for its ability to reverse kidney damage caused by diabetes, and to reverse the protein excretion which is characteristic of diabetic nephropathy.
Diabetes is the leading cause of kidney failure...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Investments, Ventures and Law Weekly